## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

	tion 1(b).	140. 000		F							ies Exchan mpany Act		934		liours	per res	porise.	0.5	
1. Name and Address of Reporting Person*  Murcko Mark					2. Issuer Name and Ticker or Trading Symbol Relay Therapeutics, Inc. [ RLAY ]							(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner						
(Last)	(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 06/03/2024							_	give title		Other (sp below)		
C/O RELAY THERAPEUTICS, INC. 399 BINNEY STREET, 2ND FLOOR					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person						
(Street) CAMBRIDGE MA 02139													Form filed by More than One Reporting Person						
(City)	(S	State)	(Zip)		_   R	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Та	ble I - Nor	n-Der	ivativ	ve Se	ecurities	s Ac	quired,	Dis	posed c	of, or Be	neficially	Owned					
1. Title of Security (Instr. 3)  2. Trans: Date (Month/L					action 2A. Deemed Execution Date, if any (Month/Day/Yea		e, Transaction Di			securities Acquired (A) posed Of (D) (Instr. 3, 4		Beneficia Owned Fo	s Form ally (D) o ollowing (I) (Ir		n: Direct   I or Indirect   E nstr. 4)   C	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) c (D)	r Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)		
			Table II -								osed of, onverti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	· 1	4. Transaction Code (Instr. r) 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		)	7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivative Securitie Beneficia Owned Following Reported	e Constant of the constant of	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisat		Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)				
Stock Option (Right to Buy)	\$6.79	06/03/2024			A		102,225		(1)		06/02/2034	Common Stock	102,225	\$0.00	102,22	25	D		

## **Explanation of Responses:**

1. This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

/s/ Brian Adams, as Attorneyin-Fact

06/05/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.